Drugs / Ad26.ZIKV.001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03356561 | Nov 2017 → Sep 2019 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad26.ZIKV.001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03356561 ↗ |
| Modality | Vaccine | “an Ad26-Vectored Anti-Zika Virus Vaccine” PMID 33587687 ↗ Feb 2021 |
| Route | Intramuscular | “administered intramuscularly as single dose and as 2-dose schedules” NCT03356561 ↗ |